Skyline Therapeutics, an innovation-driven clinical-stage gene therapy company focused on developing unique and novel solutions for rare and severe diseases, today announced a late-breaking abstract ...

Regenxbio has received a total of 8 ratings from analysts, with the consensus rating as Buy. With an average one-year price ...